Bank Julius Baer & Co. Ltd Zurich Has $45.06 Million Holdings in Haleon PLC Sponsored ADR $HLN

Bank Julius Baer & Co. Ltd Zurich raised its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 3.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,457,159 shares of the company’s stock after purchasing an additional 153,530 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Haleon were worth $45,062,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of HLN. Brighton Jones LLC acquired a new stake in Haleon in the 4th quarter valued at approximately $187,000. AQR Capital Management LLC boosted its position in Haleon by 22.5% during the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock worth $991,000 after acquiring an additional 17,720 shares during the last quarter. Focus Partners Wealth boosted its position in Haleon by 7.6% during the 1st quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock worth $752,000 after acquiring an additional 5,178 shares during the last quarter. Geneos Wealth Management Inc. grew its stake in shares of Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares in the last quarter. Finally, CW Advisors LLC raised its holdings in shares of Haleon by 11.6% in the second quarter. CW Advisors LLC now owns 25,075 shares of the company’s stock valued at $260,000 after purchasing an additional 2,601 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors.

Haleon Trading Down 1.2%

NYSE HLN opened at $8.91 on Friday. Haleon PLC Sponsored ADR has a 12 month low of $8.71 and a 12 month high of $11.42. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47. The stock has a 50 day moving average of $9.77 and a 200-day moving average of $9.97. The company has a market cap of $39.62 billion, a PE ratio of 22.85, a PEG ratio of 2.05 and a beta of 0.15.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The firm had revenue of $3.65 billion for the quarter. On average, equities research analysts anticipate that Haleon PLC Sponsored ADR will post 0.56 EPS for the current fiscal year.

Haleon Dividend Announcement

The company also recently disclosed a dividend, which was paid on Thursday, May 14th. Stockholders of record on Friday, April 10th were paid a dividend of $0.1307 per share. The ex-dividend date was Friday, April 10th. This represents a dividend yield of 266.0%. Haleon’s payout ratio is currently 64.10%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HLN. HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Argus raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Finally, Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.40.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.